Discover trends, market shifts, and competitive outlooks for the necrotizing enterocolitis industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

How Has The Necrotizing Enterocolitis Market Size Shifted, And What Is the Outlook Through 2034?

The marketplace for necrotizing enterocolitis has seen robust growth in the past years. The market which stands at $4.83 billion in 2024 is projected to rise to $5.16 billion in 2025, recording a compound annual growth rate (CAGR) of 6.8%. Factors such as a surge in the incidences of necrotizing enterocolitis, population growth, an upturn in per capita income, more government funding, and a rise in premature births have fuelled growth during the historical period.

In the coming years, the market for necrotizing enterocolitis is predicted to witness solid expansion, set to reach a valuation of $6.62 billion by 2029 with a compound annual growth rate (CAGR) of 6.4%. Several factors contribute to this anticipated growth, including escalating healthcare costs, the prevalence and occurrence of ulcerative colitis (UC), a surge in gastrointestinal diseases, an increase in the elderly and obese populations, and a swelling geriatric populace. The forecast period is expected to see significant trends such as breakthroughs in biomarker studies for early detection of NEC, advancements in non-invasive test procedures, incorporation of sophisticated monitoring systems, improvements in surgical methods, and the creation of specialized therapies.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22068&type=smp

What Are the Core Growth Drivers Propelling the Necrotizing Enterocolitis Market Forward?

The necrotizing enterocolitis market is expected to experience significant growth due to the rising instances of premature births. Preterm births—defined as the birth of a baby prior to the 37th week of pregnancy as opposed to the standard 40-week term—are becoming increasingly common. The escalation in premature births can be attributed to maternal health issues such as hypertension, diabetes, and infections, which heighten the risk of premature labor. Moreover, lifestyle choices such as smoking, substance misuse, and inadequate nourishment also increase the likelihood of preterm births. As premature babies often possess underdeveloped gastrointestinal systems, they are more vulnerable to inflammation and infection, thereby increasing the incidence of necrotizing enterocolitis (NEC). For example, Centers for Disease Control and Prevention, a government agency based in the US, reported that premature births constituted 8.67% of all US births annually in January 2024. Consequently, the rising prevalence of premature births is fueling the expansion of the necrotizing enterocolitis market.

What Segment Types Define the Necrotizing Enterocolitis Market Structure?

The necrotizing enterocolitis market covered in this report is segmented –

1) By Treatment: Total Parenteral Nutrition (TPN), Gastrointestinal Decompression, Antimicrobial Therapy, Antifungal Treatment, Paracentesis, Other Treatments

2) By Diagnosis: Laboratory Tests, Imaging Techniques

3) By Stage: Stage I (Suspected Necrotizing Enterocolitis), Stage II (Definite Necrotizing Enterocolitis), Stage III (Advanced Necrotizing Enterocolitis)

4) By Distribution Channel: Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-User: Hospitals, Neonatal Intensive Care Units (NICUs), Specialty Clinics

Subsegments:

1) By Total Parenteral Nutrition (TPN): Standard TPN Formulations, Customized Or Individualized TPN Solutions, Lipid Emulsions for TPN, Protein And Amino Acid Supplements In TPN, Micronutrient And Electrolyte-Enhanced TPN

2) By Gastrointestinal Decompression: Nasogastric Tube (NG Tube) Decompression, Orogastric Tube Decompression, Surgical Gastrostomy for Decompression, Non-Surgical Decompression Techniques

3) By Antimicrobial Therapy: Broad-Spectrum Antibiotics, Gram-Positive Coverage Antibiotics, Gram-Negative Coverage Antibiotics, Combination Antibiotic Therapy, Prophylactic Antibiotic Strategies For High-Risk Neonates

4) By Antifungal Treatment: Systemic Antifungal Therapy, Prophylactic Antifungal Therapy For Preterm Infants, Combination Antifungal And Antibiotic Therapy For Severe NEC

5) By Paracentesis: Diagnostic Paracentesis, Therapeutic Paracentesis, Guided Paracentesis using Ultrasound Or Radiological Techniques

6) By Other Treatments: Probiotics And Prebiotics for NEC Prevention, Surgical Interventions, Stem Cell Therapy And Regenerative Medicine Approaches, Immunomodulatory Therapies, Supportive Care

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=22068&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Necrotizing Enterocolitis Market?

North America was the largest region in the necrotizing enterocolitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the necrotizing enterocolitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Emerging Trends that Are Influencing theNecrotizing Enterocolitis Industry Evolution?

Several leading corporations in the necrotizing enterocolitis market have shifted their focus to the creation of innovative product solutions, such as cell-free sterile biologic solutions. This new inclination is meant to satisfy the pressing unfulfilled need for efficacious treatments and elevate outcomes for premature babies. A cell-free sterile biologic solution is a purified, aseptic liquid composed of bioactive molecules like proteins, growth factors, and cytokines culled from cultured cells but devoid of any intact cells; it’s purposed for fostering healing and reducing inflammation. For example, in December 2023, Noveome Biotherapeutics, Inc. – a U.S.-based biopharmaceutical enterprise – secured approval from the U.S. Food and Drug Administration to initiate its Phase 1-2 clinical trial for ST266, an innovative biologic geared towards treating necrotizing enterocolitis in premature infants. This development signifies a crucial landmark, as ST266 is expected to be the premier considerable therapeutic progress in the NEC field in over three decades. This aims to address a major healthcare requirement considering the disease’s elevated morbidity and lethality rates among high-risk groups.

View the full report here:

https://www.thebusinessresearchcompany.com/report/necrotizing-enterocolitis-global-market-report

What Is the Definition of the Necrotizing Enterocolitis Market?

Necrotizing enterocolitis (NEC) is a serious, potentially life-threatening gastrointestinal condition that primarily affects premature infants. It involves the inflammation and death (necrosis) of the tissue in the intestines, which can lead to perforation, infection, and other complications. The common symptoms of necrotizing enterocolitis include feeding intolerance, abdominal distension, vomiting, and changes in bowel movements.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22068

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model